fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Health Сare Committee discusses priorities, challenges and key insights for 2026

10/ 04/ 2026
  On 8 April, the Health Сare Committee of the European Business Association held its spring meeting, bringing together representatives of the pharmaceutical sector and the expert community. Participants outlined a shared vision for the development of the industry amid martial law and Ukraine’s gradual integration into the European space. Heorhii Viktorov, Chair of the Committee’s Board, opened the event and highlighted the key challenges currently facing the sector. He also noted progress in advancing priority initiatives, emphasising the importance of open dialogue within the professional community. Committee Manager Anna Bezruk presented the work plan for 2026. The priorities include European integration and regulatory harmonisation, engaging the business community in shaping a new state control authority, further development of digital solutions in the sector, and expanding patient access to treatment through the “Affordable Medicines” programme and managed entry agreements. Anna also stressed the gradual progress in implementing these priorities, particularly in strengthening dialogue with public institutions and ensuring that the expert position of the business community is taken into account in decision-making. The Committee continues to actively engage with key stakeholders — the Ministry of Health of Ukraine, the State Service of Ukraine on Medicines and Drugs Control, the State Expert Center of the Ministry of Health of Ukraine, the National Health Service of Ukraine, and others — contributing to regulatory developments and strengthening expert representation in the public domain in line with defined priorities. Presentations by experts and Committee partners focused on key insights and transformations in the sector: — Representatives of Ernst & Young — Yuliia Holovko, Director of People Advisory Services in Ukraine, and Olena Torhonska, Senior Consultant — presented an analytical overview of the labour market in the pharmaceutical sector. They highlighted changing employer expectations, global trends, and the shift towards skills-based approaches to talent management. — Dmytro Aleshko, Managing Partner at LA Law Firm, outlined recent regulatory developments in the pharmaceutical market, including the implementation of the Law of Ukraine “On Medicinal Products” No. 2469, the development of the verification system, new labelling requirements, and approaches to parallel imports, contract manufacturing, and the establishment of a state control authority. — Lana Sinichkina, Partner at Arzinger, presented an overview of legal trends in the pharmaceutical industry. She addressed issues related to competition (antitrust) regulation, the development of managed entry agreements, cases involving the prevention of “grey” imports, as well as anti-corruption and tax aspects of operations. The speaker also covered waste management and legal support for clinical trials. The event once again served as a platform for professional dialogue and networking, contributing to the consolidation of the industry community and the development of effective solutions for market growth.
01/

On 8 April, the Health Сare Committee of the European Business Association held its spring meeting, bringing together representatives of the pharmaceutical sector and the expert community. Participants outlined a shared vision for the development of the industry amid martial law and Ukraine’s gradual integration into the European space.

Heorhii Viktorov, Chair of the Committee’s Board, opened the event and highlighted the key challenges currently facing the sector. He also noted progress in advancing priority initiatives, emphasising the importance of open dialogue within the professional community.

Committee Manager Anna Bezruk presented the work plan for 2026. The priorities include European integration and regulatory harmonisation, engaging the business community in shaping a new state control authority, further development of digital solutions in the sector, and expanding patient access to treatment through the “Affordable Medicines” programme and managed entry agreements.

Anna also stressed the gradual progress in implementing these priorities, particularly in strengthening dialogue with public institutions and ensuring that the expert position of the business community is taken into account in decision-making. The Committee continues to actively engage with key stakeholders — the Ministry of Health of Ukraine, the State Service of Ukraine on Medicines and Drugs Control, the State Expert Center of the Ministry of Health of Ukraine, the National Health Service of Ukraine, and others — contributing to regulatory developments and strengthening expert representation in the public domain in line with defined priorities.

Presentations by experts and Committee partners focused on key insights and transformations in the sector:

— Representatives of Ernst & YoungYuliia Holovko, Director of People Advisory Services in Ukraine, and Olena Torhonska, Senior Consultant — presented an analytical overview of the labour market in the pharmaceutical sector. They highlighted changing employer expectations, global trends, and the shift towards skills-based approaches to talent management.

Dmytro Aleshko, Managing Partner at LA Law Firm, outlined recent regulatory developments in the pharmaceutical market, including the implementation of the Law of Ukraine “On Medicinal Products” No. 2469, the development of the verification system, new labelling requirements, and approaches to parallel imports, contract manufacturing, and the establishment of a state control authority.

Lana Sinichkina, Partner at Arzinger, presented an overview of legal trends in the pharmaceutical industry. She addressed issues related to competition (antitrust) regulation, the development of managed entry agreements, cases involving the prevention of “grey” imports, as well as anti-corruption and tax aspects of operations. The speaker also covered waste management and legal support for clinical trials.

The event once again served as a platform for professional dialogue and networking, contributing to the consolidation of the industry community and the development of effective solutions for market growth.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
Nationwide Minute of Silence
01:00
09:00
Nationwide Minute of Silence
Let us honor the memory of all those who lost their lives in russia’s war against Ukraine
00:43

Spelling error report

The following text will be sent to our editors: